Cochlear Implant — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A cochlear implant is an electronic hearing prosthesis surgically implanted in the inner ear to provide sound perception to individuals with severe-to-profound sensorineural hearing loss who do not benefit adequately from conventional acoustic hearing aids. Unlike hearing aids that amplify sound, a cochlear implant bypasses the damaged hair cells of the cochlea and directly stimulates the surviving auditory nerve fibres with electrical impulses, transmitting speech and environmental sound information to the brain. The system has two components: an internal component (receiver-stimulator unit implanted under the skin behind the ear and a flexible electrode array inserted into the cochlea) and an external component (a sound processor worn behind the ear or off the ear, which captures sound, processes it digitally, and transmits signals to the internal component via a transcutaneous radiofrequency link). Modern cochlear implant systems from manufacturers including Cochlear Corporation, MED-EL, Advanced Bionics, and Oticon Medical achieve 12–22 active electrode contacts within the cochlear spiral, providing frequency-specific electrical stimulation across the tonotopic map of the cochlea. A cochlear implant is an electronic hearing prosthesis surgically implanted in the inner ear to provide sound perception to individuals with severe-to-profound sensorineural hearing loss who do not benefit adequately from conventional acoustic hearing aids. Unlike hearing aids that amplify sound, a cochlear implant bypasses the damaged hair cells of the cochlea and directly stimulates the surviving auditory nerve fibres via an electrode array inserted into the scala tympani of the cochlea. The device consists of an implanted receiver-stimulator (inserted behind the ear under the skin) connected to an intra-cochlear electrode array, and an external sound processor worn behind or off the ear. Cochlear implants have been approved for clinical use since 1984 and represent one of the most successful neural prostheses ever developed. Over 1 million people worldwide have received cochlear implants. The procedure is performed by otolaryngologists (ENT surgeons) or neurotologists with specific cochlear implant training at designated implant centres.

Cochlear implant candidacy is determined through comprehensive audiological assessment. NICE (UK) and FDA criteria include: bilateral severe-to-profound sensorineural hearing loss (pure tone average above 70–80 dB HL in the better-hearing ear), inadequate benefit from optimally fitted bilateral hearing aids (defined as sentence recognition in quiet below 50% at 65 dB SPL in adults, or failure to achieve adequate speech and language developmental milestones in children), cochlear anatomy suitable for electrode insertion (confirmed by CT temporal bone and MRI brain), absence of medical contraindications to general anaesthesia, and realistic expectations regarding the time and commitment required for rehabilitation. Children benefit from implantation as early as 6–12 months of age; earlier implantation during the critical period of auditory cortex development (birth to age 3.5 years) is associated with substantially better spoken language outcomes. Adults who are post-lingually deaf (deafened after speech development) generally achieve better speech recognition outcomes than those who have been profoundly deaf since birth (pre-lingually deaf adults). Bilateral cochlear implantation improves sound localisation, speech understanding in noise, and quality of life compared with unilateral implantation and is increasingly supported by NHS commissioning guidelines.

Cochlear implantation is performed under general anaesthesia with intraoperative facial nerve monitoring throughout the procedure. The patient is positioned supine with the head turned to expose the operated ear. A post-auricular incision is made behind the ear. A mastoidectomy — drilling of the mastoid bone — is performed to expose the middle ear through the posterior tympanotomy approach, accessing the round window or cochleostomy site where the electrode array will be inserted. A bony bed is drilled in the mastoid cortex behind the ear to seat the implant body (receiver-stimulator). The electrode array is carefully inserted into the scala tympani of the cochlea using a 'soft surgery' technique — slow, gentle insertion with angled tools — to minimise trauma to residual hair cells and the basilar membrane, preserving any residual acoustic hearing (hearing preservation surgery). The implant is secured, the wound closed in layers, and a pressure dressing applied. Intraoperative electrical testing confirms electrode impedances and auditory nerve response. Total surgical time is 2–3 hours. Cochlear implantation is performed under general anaesthesia with intraoperative facial nerve monitoring. The patient is positioned supine with the head turned to expose the operated ear. A post-auricular incision is made behind the ear. A mastoidectomy — drilling of the mastoid bone — creates access to the middle ear. A posterior tympanotomy (opening between the mastoid and middle ear through the facial recess) provides access to the round window niche without disturbing the ear canal. The round window membrane is opened or a cochleostomy (small opening) drilled at the promontory adjacent to the round window to access the scala tympani. The electrode array is carefully inserted into the scala tympani under real-time intraoperative neural response telemetry (NRT) to confirm electrical stimulation of auditory nerve fibres. The implant body is seated in a bone-anchored well in the temporal bone. Intraoperative neural telemetry confirms electrode function and impedances. The wound is closed in layers and a bandage applied. Procedure time is 2–3 hours.

Cochlear implantation is one of the most evidence-supported interventions in medicine, with decades of outcome data demonstrating transformative benefit. In post-lingually deaf adults, cochlear implants achieve sentence recognition scores of 60–90% in quiet listening conditions — a dramatic improvement from near-zero pre-implantation. The majority of adult recipients can use the telephone effectively within 6–12 months of activation. Quality of life, social participation, employment, and independence all improve significantly, with validated reductions in depression and social isolation. Pre-lingually deaf children implanted before 18 months of age develop spoken language skills that approach age-appropriate norms in many cases, enabling mainstream school attendance. Children implanted before age 3 years achieve significantly better language outcomes than those implanted later, underscoring the importance of early identification through universal newborn hearing screening and prompt referral. Bilateral cochlear implantation significantly improves speech understanding in background noise (signal-to-noise ratio benefit of 2–4 dB compared with unilateral) and restores sound localisation to near-normal accuracy. Patient and parental satisfaction ratings consistently exceed 85–90% in systematic reviews.

Cochlear implantation is a low-risk surgical procedure with a serious complication rate below 5% at experienced centres. Loss of residual acoustic hearing in the implanted ear occurs in approximately 20–50% of cases — however, many recipients had non-functional residual hearing, and modern hearing-preservation techniques reduce this risk. Device malfunction requiring surgical reimplantation occurs in approximately 1–5% of cases over the device lifetime and is managed by replacing the internal component with the electrode array in situ where possible. Wound infection occurs in 1–2% and is managed with antibiotics; device explantation is rarely required. Facial nerve injury from the mastoid drilling or electrode insertion occurs in fewer than 0.1% at specialist centres; continuous intraoperative nerve monitoring prevents this complication. Bacterial meningitis risk is slightly elevated in cochlear implant recipients; pneumococcal and Haemophilus influenzae b vaccination is mandatory before implantation. Electrode-related complications — misplacement, kinking, or tip fold-over — may reduce performance and occasionally require revision surgery. Vestibular dysfunction causing temporary dizziness occurs in 10–20% of patients and usually resolves within weeks.

Hospital stay is typically 1–2 days. The post-auricular wound heals over 3–4 weeks; swimming is avoided until wound healing is complete. The external sound processor is not fitted at surgery — activation ('switch-on') is scheduled at 3–4 weeks post-operatively when swelling has resolved and the wound is healed. At activation, the audiologist uses specialist software to programme the processor, setting the electrical stimulation map (programme) based on threshold and comfort levels for each electrode. Initial sound quality is typically described as robotic, electronic, or unnatural — this is expected and improves substantially over weeks to months as the auditory cortex adapts to electrical stimulation (auditory plasticity). An intensive programme of auditory training and speech-language therapy follows activation: adults typically attend speech therapy for 6–12 months, focusing on sound discrimination, speech perception training, and telephone skills. Paediatric recipients receive intensive early intervention with an auditory-verbal therapy programme or total communication approach, with therapy continuing throughout childhood. Sound processors require battery replacement or recharging daily; the external component should be removed during contact water sports or showering unless the processor has a waterproof cover.